NewAmsterdam Pharma Company N.V. (NAMS) Financial Ratios
6 years of historical data (2020–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: 19.79
30Y Low19.8·High19.8
P/B Ratio
↑
5.93
↑+88% vs avg
5yr avg: 3.16
30Y Low0.5·High5.9
ROE
↑
-28.3%
↓+21% vs avg
5yr avg: -35.7%
30Y Low-49%·High-6%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
NAMS Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
NewAmsterdam Pharma Company N.V. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Market Cap | $4.1B | $4.0B | $2.4B | $918M | $207M | $173M | — |
| Enterprise Value | $3.7B | $3.5B | $1.7B | $577M | $-260870039 | $113M | — |
| P/E Ratio → | -20.25 | — | — | — | — | — | — |
| P/S Ratio | 184.11 | 178.34 | 53.22 | 65.13 | 2.01 | — | — |
| P/B Ratio | 5.93 | 5.87 | 3.20 | 3.18 | 0.48 | 3.06 | — |
| P/FCF | — | — | — | — | 19.79 | — | — |
| P/OCF | — | — | — | — | 19.38 | — | — |
P/E links to full P/E history page with 30-year chart
NAMS EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 156.57 | 36.29 | 40.98 | -2.54 | — | — |
| EV / EBITDA | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | -24.98 | — | — |
NAMS Profitability
Margins and return-on-capital ratios measuring operating efficiency
NewAmsterdam Pharma Company N.V. earns an operating margin of -1002.9%. Operating margins have expanded from -1298.6% to -1002.9% over the past 3 years, signaling improving operational efficiency. A negative ROE of -28.3% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Gross Margin | 99.7% | 99.7% | 100.0% | 100.0% | 100.0% | — | — |
| Operating Margin | -1002.9% | -1002.9% | -386.9% | -1298.6% | -3.5% | — | — |
| Net Profit Margin | -905.7% | -905.7% | -530.3% | -1255.8% | -22.0% | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| ROE | -28.3% | -28.3% | -46.2% | -49.3% | -9.3% | -45.4% | -5.5% |
| ROA | -24.9% | -24.9% | -39.9% | -42.9% | -8.3% | -40.2% | -5.0% |
| ROIC | -188.2% | -188.2% | — | — | — | -42.8% | — |
| ROCE | -31.3% | -31.3% | -33.4% | -49.5% | -1.4% | -35.6% | -4.7% |
NAMS Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $490M exceeds total debt of $202000, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Debt / EBITDA | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.72 | -1.02 | -1.18 | -1.09 | -1.06 | -0.01 |
| Net Debt / EBITDA | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | -44.77 | — | — |
| Interest Coverage | — | — | — | -26.02 | -77.86 | -100.67 | — |
Net cash position: cash ($490M) exceeds total debt ($202000)
NAMS Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
NewAmsterdam Pharma Company N.V.'s current ratio of 7.88x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 6.95x to 7.88x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Current Ratio | 7.88 | 7.88 | 8.08 | 6.95 | 13.26 | 5.96 | 7.90 |
| Quick Ratio | 7.88 | 7.88 | 8.08 | 6.95 | 13.26 | 5.96 | 7.90 |
| Cash Ratio | 7.42 | 7.42 | 7.80 | 6.82 | 12.97 | 5.37 | 5.77 |
| Asset Turnover | — | 0.03 | 0.05 | 0.04 | 0.21 | — | — |
| Inventory Turnover | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 375.53 | 170.67 | 48.73 | — | — | — |
NAMS Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
NewAmsterdam Pharma Company N.V. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | 5.1% | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Shares Outstanding | — | $114M | $94M | $82M | $19M | $18M | $18M |
Peer Comparison
Compare NAMS with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 NAMSYou | $4B | -20.3 | — | — | 99.7% | -1002.9% | -28.3% | -188.2% | — |
 ESPR | $649M | -28.4 | 17.0 | — | 67.9% | 15.0% | — | 66.5% | 9.1 |
 MDGL | $12B | -40.8 | — | — | 94.1% | -31.3% | -42.5% | -29.4% | — |
 LNTH | $6B | 27.5 | 15.1 | 17.3 | 61.1% | 20.2% | 21.4% | 30.6% | 0.0 |
 PFE | $144B | 18.6 | 10.3 | 15.9 | 70.3% | 24.7% | 8.9% | 7.5% | 3.3 |
 MRK | $275B | 15.3 | 10.6 | 22.3 | 72.0% | 36.2% | 36.9% | 22.0% | 1.7 |
 NVS | $283B | 20.6 | 13.7 | 16.0 | 75.0% | 31.2% | 31.0% | 18.8% | 1.7 |
 AZN | $282B | 27.8 | 15.7 | 23.9 | 81.9% | 23.4% | 22.9% | 14.9% | 1.5 |
 AMGN | $176B | 22.9 | 14.0 | 21.7 | 70.8% | 29.1% | 106.1% | 14.8% | 3.4 |
 REGN | $73B | 16.8 | 17.5 | 17.8 | 85.4% | 24.9% | 14.9% | 8.9% | 0.7 |
 IQV | $29B | 21.6 | 12.5 | 14.0 | 26.3% | 14.0% | 21.4% | 8.7% | 4.7 |
| Healthcare Median | — | 21.4 | 14.0 | 18.3 | 64.2% | -5.1% | -32.3% | -10.9% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 6 years · Updated daily
See NAMS's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs NAMS Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare NAMS vs ESPR
Side-by-side business, growth, and profitability comparison vs Esperion Therapeutics, Inc..
Start ComparisonNAMS — Frequently Asked Questions
Quick answers to the most common questions about buying NAMS stock.
What is NewAmsterdam Pharma Company N.V.'s P/E ratio?
NewAmsterdam Pharma Company N.V.'s current P/E ratio is -20.3x. This places it at the 50th percentile of its historical range.
What is NewAmsterdam Pharma Company N.V.'s ROE?
NewAmsterdam Pharma Company N.V.'s return on equity (ROE) is -28.3%. The historical average is -30.7%.
Is NAMS stock overvalued?
Based on historical data, NewAmsterdam Pharma Company N.V. is trading at a P/E of -20.3x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are NewAmsterdam Pharma Company N.V.'s profit margins?
NewAmsterdam Pharma Company N.V. has 99.7% gross margin and -1002.9% operating margin.